Carlyle & SK Capital to Acquire Bluebird Bio

Shots: Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 As per the deal, Bluebird stockholders will get $3/share & contingent…

ByRidhi RastogiFebruary 24, 2025

NEWS

AstraZeneca Purchases FibroGen China for ~$160M

Shots: AstraZeneca has purchased FibroGen’s China subsidiary for ~$160M ($85M enterprise value + ~$75M net cash) with closing expected in mid-2025, obtaining full rights to roxadustat in China The sale allows FibroGen to repay its Morgan Stanley Tactical Value loan & extend its cash runway to 2027 for advancing FG-3246 in P-II trial for…

ByRidhi RastogiFebruary 21, 2025

NEWS

Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M

Shots: Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25 Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing The combined…

ByRidhi RastogiFebruary 21, 2025

NEWS

Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B

Shots: Bain Capital has signed to acquire Mitsubishi Tanabe Pharma in a carve-out deal from Mitsubishi Chemical Group at ~510 billion JPY (3.3 billion USD), is led by Bain Capital’s Private Equity teams in Asia, North America, and its Life Sciences team. The transaction is expected to close in Q3’25, pending regulatory approval, shareholder…

ByRidhi RastogiFebruary 7, 2025

NEWS

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Shots: Alumis & ACELYRIN have entered into a definitive agreement to merge, with ACELYRIN stockholders receiving 0.4274 Alumis shares/share, owning 45% of the combined entity - "Alumis"; closing expected in Q2’25 As of Dec 31, 2024, Alumis & ACELYRIN had ~$289M & ~$448M in cash as well as investments, respectively, with a pro forma…

ByRidhi RastogiFebruary 7, 2025

NEWS

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M

Shots: Relmada acquired the Sepranolone from Asarina for $3.12M via an asset purchase agreement to develop it as a potential treatment for Tourette syndrome (TS) & other compulsive disorders Sepranolone (10mg, BIW, SC) is a GABAA-modulating steroid antagonist that is being investigated in a P-IIa trial, assessing it with SoC vs SoC alone in…

ByRidhi RastogiFebruary 7, 2025

NEWS

Lantheus Holdings to Acquire Evergreen Theragnostics for ~$1B

Shots: Lantheus will acquire Evergreen Theragnostics for $250M upfront plus ~$752.5M development & sales milestones related to Octevy & other assets in an all-cash transaction, with closing anticipated in H2’25 pending regulatory approvals The acquisition will add Evergreen’s Octevy (registrational-stage PET imaging agent for somatostatin receptor +ve NETs in adults & pediatrics) complementing Lantheus'…

BySenior EditorJanuary 29, 2025

NEWS

Zimmer Biomet to Acquire Paragon 28 for ~$1.2B

Shots: Zimmer Biomet has agreed to acquire Paragon 28 for $13.00/share in cash with an equity value of ~$1.1B & enterprise value of ~$1.2B. Closing is expected in H1’25 As per the terms, shareholders will also get a non-tradeable CVR of $1/share on achieving revenue milestones, which is payable from $0 to $1 (calculated linearly)…

BySenior EditorJanuary 29, 2025

NEWS

Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

Shots: Eli Lilly to acquire Scorpion, plus its leading asset STX-478, for ~2.5B in cash, incl. upfront, regulatory & sales milestones through a definitive agreement As per the terms, Scorpion will form an independent company owned by its current shareholders with Lilly’s minority stake to hold its employees & non-PI3Kα pipeline assets STX-478 (oral,…

ByDipanshu DixitJanuary 14, 2025

NEWS

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

Shots: J&J entered into a definitive agreement to acquire Intra-Cellular Therapies, incl. its drugs Caplyta & ITI-1284, for a total equity value of ~14.6B (cash + debt), with shareholders receiving $132/share in cash, making the latter private In Dec 2024, the latter filed an sNDA to the US FDA for Caplyta as adj. therapy…

ByDipanshu DixitJanuary 14, 2025

Carlyle & SK Capital to Acquire Bluebird Bio

AstraZeneca Purchases FibroGen China for ~$160M

Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M

Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M

Lantheus Holdings to Acquire Evergreen Theragnostics for ~$1B

Zimmer Biomet to Acquire Paragon 28 for ~$1.2B

Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

Contact US

OUR INFORMATION

FOLLOW US